ASAkpay Sh. Sarybaev

Akpay Sh. Sarybaev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Akpay Sh. Sarybaev has a total of 651 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Association of ultrasound parameters of visceral and subcutaneous adipose tissue with carotid artery atherosclerosis in the kyrgyz ethnic group

    by A.G. Polupanov, K.N. Suiunov, A.T. Mamazhakypov, A.A. Garanin, M. Sherikbai Kyzy, N.B. Cheskidova, A.S. Sydykov, A.SH. Sarybaev

    Background. Visceral obesity is a more important marker of cardiometabolic risk than overall adiposity or subcutaneous fat accumulation. However, there are no data on association between ultrasound-assessed regional adipose tissue distribution and subclinical atherosclerosis in the Kyrgyz ethnic group. Objective. To assess association of ultrasound parameters of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) with carotid atherosclerosis (CA) in the Kyrgyz ethnic group. Material and methods. A cross-sectional analytical observational study included 108 respondents aged 19—65 years who attended a cardiology clinic for preventive evaluation. Demographic and behavioral risk factors, anthropometric parameters, blood pressure, glucose and lipid metabolism with calculation of HOMA-IR, ultrasound parameters of VAT and SAT, and carotid artery ultrasound data were assessed in all participants. Associations between ultrasound parameters and CA were analyzed using binary logistic regression. Results. CA was detected in 26 out of 108 participants. In between-group comparisons, all ultrasound parameters of VAT and SAT were higher in individuals with CA. In addition, ultrasound parameters of adipose tissue were associated with adverse cardiometabolic profile, including anthropometric obesity measures, blood pressure, insulin resistance, and markers of metabolic liver injury. After multivariable adjustment, only abdominal VAT thickness (odds ratio 1.056; 95% confidence interval 1.007—1.107; p=0.025) and renal VAT thickness (odds ratio 1.107; 95% confidence interval 1.022—1.199; p=0.013) remained independently associated with CA. SAT parameters were not associated with CA. In ROC analysis, abdominal VAT ≥33.5 mm and renal VAT ≥19 mm showed high sensitivity and moderate specificity for CA. Conclusion. In this cohort, greater abdominal and renal VAT thickness was independently associated with CA, whereas SAT parameters did not demonstrated these correlations.

  • Open Access

    Osteopontin in Atrial Fibrillation and Atrial Remodeling

    by Argen Mamazhakypov, Balram Neupane, Akpay Sarybaev, Akylbek Sydykov, Ralph T. Schermuly, Michael Gramlich, Kabita Pradhan

    Atrial fibrillation is the most prevalent sustained cardiac arrhythmia, characterized by limited therapeutic options because of incompletely understood mechanisms of its development. The key underlying pathogenetic mechanisms involve atrial myocardial inflammation and fibrosis in response to pressure or volume overload, myocardial infarction, as well as metabolic alterations. Recent studies have highlighted the crucial role of osteopontin in diverse cardiovascular diseases, including atrial fibrillation. Osteopontin is a multifunctional extracellular matrix protein that has recently emerged as a potential mediator of atrial remodeling and arrhythmogenesis. Human studies have revealed that circulating osteopontin levels can serve as a valuable biomarker for atrial fibrillation and its progression. Furthermore, in vitro studies have demonstrated that osteopontin modulates several key cellular processes involved in atrial inflammation and fibrosis, including fibroblast activation, extracellular matrix remodeling, and proinflammatory cytokine production. This review critically examines the available evidence on the role of osteopontin in atrial remodeling and arrhythmia starting from the molecular mechanisms by which osteopontin contributes to structural and electrical remodeling of the atria, to its potential as a biomarker for atrial fibrillation.


  • Open Access

    INFARCT-REDUCING EFFECT OF DELTORPHIN II IN REPERFUSION OF THE HEART. THE ROLE OF NO-SYNTHASE, GUANYLYLCYCLASE, cGMP, MPT PORE

    by Сергей Валентинович Попов, Alexandr V. Mukhomedzyanov, Борис Константинович Курбатов, Вячеслав Николаевич Азев, Галина Зиновьевна Суфианова, Maria S. Khlestkina, Акпай Шогаибович Сарыбаев, Леонид Николаевич Маслов, Александр Валерьевич Мухомедзянов, Мария Сергеевна Хлёсткина

    HighlightsThe selective δ2-opioid receptor agonist deltorphin II increases cardiac tolerance to reperfusion by activating guanylyl cyclase, stimulating cGMP synthesis, activating sarcKATP channel, and blocking MPT pore. Aim. To evaluate the role of NO-synthase, guanylyl cyclase, cGMP, MPT pore in the infarct-limiting effect of deltorphin II in the model of ischemia and reperfusion of the rat heart.Methods. Coronary artery occlusion (45 min) and reperfusion (2 h) were performed in rats anesthetized with chloralose. The selective δ2-opioid receptor agonist deltorphin II was administered intravenously at a dose of 120 µg/kg 5 min before reperfusion. The NO synthase inhibitor L-NAME, the guanylyl cyclase inhibitor ODQ, and the MPT pore blocker atractyloside were administered intravenously 10 min before reperfusion. The cAMP and cGMP levels were measured in myocardial tissue.Results. Deltorphin II causes a decrease in infarct size by about 50%. L-NAME did not affect the cardioprotective effect of deltorphin. Atractyloside and ODQ completely abolished the infarct-reducing effect of deltorphin. Deltorphin II caused an increase in the cGMP level in the myocardium, but did not affect the cAMP level.Conclusion. Analysis and generalization of obtained data and the results of previous studies indicate that the infarct-limiting effect of deltorphin II is associated with activation of δ2-opioid receptors located in cardiomyocytes, followed by activation of heme oxygenase-1, an increase in CO production, stimulation of guanylyl cyclase, and activation of protein kinase G. The putative end-effectors are MPT pore and sarcKATP channel. In turn, NO synthase is not involved in signal transduction from δ2-OR to the MPT pore and sarcKATP channel.


  • Open Access

    Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension (2023)

    by I. E. Chazova, T. V. Martynyuk, A. A. Shmalts, V. V. Gramovich, N. M. Danilov, T. N. Veselova, I. Z. Korobkova, A. Sh. Sarybaev, O. V. Stukalova, V. A. Azizov, et al.

    Евразийские рекомендации по диагностике и лечению лёгочной гипертензии (2023)


  • Open Access

    Mast Cells in Cardiac Remodeling: Focus on the Right Ventricle

    by Argen Mamazhakypov, Abdirashit Maripov, Akpay S. Sarybaev, Ralph Theo Schermuly, Akylbek Sydykov

    In response to various stressors, cardiac chambers undergo structural remodeling. Long-term exposure of the right ventricle (RV) to pressure or volume overload leads to its maladaptive remodeling, associated with RV failure and increased mortality. While left ventricular adverse remodeling is well understood and therapeutic options are available or emerging, RV remodeling remains underexplored, and no specific therapies are currently available. Accumulating evidence implicates the role of mast cells in RV remodeling. Mast cells produce and release numerous inflammatory mediators, growth factors and proteases that can adversely affect cardiac cells, thus contributing to cardiac remodeling. Recent experimental findings suggest that mast cells might represent a potential therapeutic target. This review examines the role of mast cells in cardiac remodeling, with a specific focus on RV remodeling, and explores the potential efficacy of therapeutic interventions targeting mast cells to mitigate adverse RV remodeling.


  • Open Access

    Mast Cells in Cardiac Remodeling: Focus on the Right Ventricle

    by Argen Mamazhakypov, Abdirashit Maripov, Akpay S. Sarybaev, Ralph Theo Schermuly, Akylbek Sydykov

    In response to various stressors, cardiac chambers undergo structural remodeling. Long-term exposure of the right ventricle (RV) to pressure or volume overload leads to its maladaptive remodeling, associated with RV failure and increased mortality. While left ventricular adverse remodeling is well understood and therapeutic options are available or emerging, RV remodeling remains underexplored and no specific therapies are currently available. Accumulating evidence implicates a role of mast cells in RV remodeling. Mast cells produce and release numerous inflammatory mediators, growth factors and proteases that can adversely affect cardiac cells, thus contributing to cardiac remodeling. Recent experimental findings suggest that mast cells might represent a potential therapeutic target. This review examines the role of mast cells in cardiac remodeling with specific focus on RV remodeling and explores the potential efficacy of therapeutic interventions targeting mast cells to mitigate adverse RV remodeling.


  • Open Access

    Osteopontin in Pulmonary Hypertension

    by Argen Mamazhakypov, Abdirashit Maripov, Akpay S. Sarybaev, Ralph Theo Schermuly, Akylbek Sydykov

    Pulmonary hypertension (PH) is a pathological condition with multifactorial etiology, which is characterized by elevated pulmonary arterial pressure and pulmonary vascular remodeling. The underlying pathogenetic mechanisms remain poorly understood. Accumulating clinical evidence suggests that circulating osteopontin may serve as a biomarker of PH progression, severity, and prognosis, as well as an indicator of maladaptive right ventricular remodeling and dysfunction. Moreover, preclinical studies in rodent models have implicated osteopontin in PH pathogenesis. Osteopontin modulates a plethora of cellular processes within the pulmonary vasculature, including cell proliferation, migration, apoptosis, extracellular matrix synthesis, and inflammation via binding to various receptors such as integrins and CD44. In this article, we provide a comprehensive overview of the current understanding of osteopontin regulation and its impact on pulmonary vascular remodeling, as well as consider research issues required for the development of therapeutics targeting osteopontin as a potential strategy for the management of PH.


  • Open Access

    Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022)

    by I. E. Chazova, N. M. Chikhladze, N. V. Blinova, Zh. E. Belaya, N. M. Danilov, E. M. Elfimova, A. Yu. Litvin, L. Ya. Rozhinskaya, N. Yu. Sviridenko, M. Yu. Shvetsov, et al.

    Disclaimer. The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.


  • Open Access

    Clinical features of post-COVID period. Results of an International Register "Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)" (12-month follow-up)

    by G. P. Arutyunov, E. I Tarlovskaya, A. G. Arutyunov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, et al.

    Aim. To investigate on post-COVID period in patients of the Eurasian region.Material and methods. A total of 9364 consecutively hospitalized patients were included in ACTIV registry. Enrollment of patients began on June 29, 2020, and was completed on March 30, 2021, corresponding to the first and second waves of the pandemic. Demographic, clinical, and laboratory data, computed tomography (CT) results, information about inhospital clinical course and complications of COVID-19 during hospitalization were extracted from electronic health records using a standardized data collection form. The design included follow-up telephone interviews with a standard questionnaire at 3, 6, and 12 months to examine the course of post-COVID period.Results. According to ACTIV register, 63% of patients after COVID-19 had new adverse symptoms or exacerbations of the existing symptoms lasting for up to 1 year. After hospital discharge, 79,8% of patients sought unscheduled medical attention in the first 3 months, 79,1% at 4-6 months, and 64,8% at 7-12 months. Readmission rate was 11,8% in the first 3 months, 10,9% at 4-6 months, and 10,1% at 7-12 months. The most common reasons for unscheduled treatment in the first 3 months were uncontrolled hypertension, decompensated type 2 diabetes, destabilization of coronary artery disease, gastrointestinal disease, AF episodes, exacerbation of asthma and chronic obstructive pulmonary disease, decompensated heart failure (HF). The 12-month mortality of COVID-19 survivors after the discharge was 3,08%. Multivariate analysis showed that independent risk factors for fatal outcome were age (direct correlation), the levels of hemoglobin (inverse correlation), oxygen saturation (inverse correlation), and aspartate aminotransferase (direct correlation), as well as class III-IV HF, prior stroke, cancer, inhospital acute kidney injury. Based on these identified risk factors, a nomogram was constructed to determine the 3-month mortality risk after discharge.Conclusion. Analysis of ACTIV register showed that end of the acute phase of COVID-19 does not imply a complete recovery.


  • Open Access

    Circulating Microparticles Are Differentially Increased in Lowlanders and Highlanders with High Altitude Induced Pulmonary Hypertension during the Cold Season

    by Akylbek Sydykov, Aleksandar Petrovic, Abdirashit M. Maripov, Marija Gredic, Daniel Gerd Bermes, Nadira Kushubakova, Kubatbek Muratali Uulu, Christina Pilz, Meerim Cholponbaeva, Melis Duishobaev, et al.

    The role of microparticles (MPs) and cold in high altitude pulmonary hypertension (HAPH) remains unexplored. We investigated the impact of long-term cold exposure on the pulmonary circulation in lowlanders and high-altitude natives and the role of MPs. Pulmonary hemodynamics were evaluated using Doppler echocardiography at the end of the colder and warmer seasons. We further examined the miRNA content of MPs isolated from the study participants and studied their effects on human pulmonary artery smooth muscle (hPASMCs) and endothelial cells (hPAECs). Long-term exposure to cold environment was associated with an enhanced pulmonary artery pressure in highlanders. Plasma levels of CD62E-positive and CD68-positive MPs increased in response to cold in lowlanders and HAPH highlanders. The miRNA-210 expression contained in MPs differentially changed in response to cold in lowlanders and highlanders. MPs isolated from lowlanders and highlanders increased proliferation and reduced apoptosis of hPASMCs. Further, MPs isolated from warm-exposed HAPH highlanders and cold-exposed highlanders exerted the most pronounced effects on VEGF expression in hPAECs. We demonstrated that prolonged exposure to cold is associated with elevated pulmonary artery pressures, which are most pronounced in high-altitude residents. Further, the numbers of circulating MPs are differentially increased in lowlanders and HAPH highlanders during the colder season.